---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-278810"
form_type: "8-K"
ticker: "AURA"
cik: "0001501796"
company_name: "Aura Biosciences, Inc."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:19:10.606808+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aura Biosciences Q3 net loss $26.1M; Phase 3 CoMpass data expected Q4 2027

## Summary
- Net loss of $26.1M in Q3 2025 vs $21.0M in Q3 2024; R&D expenses rose to $22.2M from $17.0M.
- Cash and marketable securities $161.9M; cash runway into first half 2027.
- Phase 3 CoMpass trial in early choroidal melanoma: enrollment completion expected 2026, topline data Q4 2027.
- Phase 1b/2 NMIBC trial on track for initial data mid-2026; immune profiling shows cold-to-hot tumor conversion.
- First patient dosed in Phase 2 choroidal metastases trial; entry criteria expanded to include all solid tumors.

## SEC filing metadata
- accession: 0001193125-25-278810
- form_type: 8-K
- ticker: AURA
- cik: 0001501796
- company_name: Aura Biosciences, Inc.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501796/000119312525278810/0001193125-25-278810-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501796/000119312525278810/aura-20251113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-278810
- JSON: https://secwatch.observer/filing/0001193125-25-278810.json
- Plain text: https://secwatch.observer/filing/0001193125-25-278810.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.